UiPath announced it is expanding its alliance with Deloitte through the launch of Deloitte’s Agentic ERP offering.

UiPath, Inc. (NYSE:PATH) is one of the cheap AI stocks to buy in 2026. On February 23, 2026, UiPath announced a suite of agentic AI solutions for healthcare providers and payers, targeting ...

"We're also providing a scalable blueprint to expand agentic automation across the enterprise, transforming how business users engage with ERP through seamless collaboration betwe ...

UiPath (PATH) heads into its fiscal fourth quarter report today, with investors weighing its history of meeting guidance against softer sector sentiment, fresh healthcare agentic AI launches, and new ...

Enterprise automation budgets are shifting from point tools to platforms. Buyers want governance, reuse, and faster time to ...

MINNEAPOLIS--(BUSINESS WIRE)--Deluxe, a trusted Payments and Data company, today announced it has been named an UiPath AI25 Award Winner. The annual award program identifies the 25 most innovative ...

NEW YORK & BOCA RATON, Fla.--(BUSINESS WIRE)--UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced that it is transforming operations for Omega Healthcare, a ...

UiPath develops enterprise automation technology platforms; Robotic process automation enables digital workflow transformation; UiPath software integrates artificial i ...

UiPath Inc (NYSE: PATH) opened in the red this morning after the firm’s muted full-year outlook tempered its Q4 beat and announcement of a new $500 million share repurchase programme. To some, the ...

On March 12, 2026, investors weighed UiPath’s first full-year profit against slowing growth and divided Wall Street views.

UiPath works with a technology known as agentic automation, which is the process of using artificial intelligence to carry out multi-step tasks quickly with limited human input. U ...

It's still too early to say whether UiPath will ultimately end up, on net, as benefitting from or being harmed by AI adoption. Read why PATH stock is a Sell.